{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostate-cancer/management/complications-adverse-effects/","result":{"pageContext":{"chapter":{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects","depth":2,"htmlHeader":"<!-- begin field 7376c1c2-b7b8-43fa-98cd-01f6ebaa4006 --><h2>Scenario: Management of complications of prostate cancer and adverse effects of treatments</h2><!-- end field 7376c1c2-b7b8-43fa-98cd-01f6ebaa4006 -->","summary":"Covers how men with prostate cancer are followed up, what complications and adverse effects of treatment may need to be recognized or managed in primary care, the approach to palliative care, and advice on information resources and support groups for men with complications or adverse effects.","htmlStringContent":"<!-- begin item 3924321f-f067-403d-8e9d-537e2f0b9e35 --><!-- begin field bc6c10f6-c84d-4753-a050-acd900adef0b --><p>From age 30 years onwards (Male).</p><!-- end field bc6c10f6-c84d-4753-a050-acd900adef0b --><!-- end item 3924321f-f067-403d-8e9d-537e2f0b9e35 -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","lastRevised":"Last revised in October 2017","chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","fullItemName":"Management","slug":"management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"b35b79cf-36d2-5154-a2c8-24217730c9d5","slug":"follow-up-monitoring","fullItemName":"Follow up and monitoring","depth":3,"htmlHeader":"<!-- begin field 8945254f-1f64-48b7-a9ce-a75400fc378b --><h3>How should I follow up and monitor men with prostate cancer?</h3><!-- end field 8945254f-1f64-48b7-a9ce-a75400fc378b -->","summary":null,"htmlStringContent":"<!-- begin item 73b7f09c-7e8c-4616-b0b0-a75400fc36de --><!-- begin field 397a8ddc-42da-487e-a9dd-a75400fc378b --><ul><li><strong>Men with prostate cancer should be followed up in primary care in line with locally agreed protocols.</strong></li><li><strong>For all men,</strong> review and manage:<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/background-information/complications/\">Complications</a> of the disease, including pain, lower urinary tract symptoms, and symptoms of spinal cord compression.</li><li>Adverse effects from treatment, including <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/complications-adverse-effects/#sexual-dysfunction\">sexual dysfunction</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/complications-adverse-effects/#urinary-symptoms\">urinary incontinence</a>.<ul><li>Adverse effects of androgen withdrawal include change in body shape and weight gain, tiredness, hot flushes, loss of libido, erectile dysfunction, gynaecomastia, and loss of bone density.</li></ul></li><li>Quality of life.</li></ul></li><li><strong>For men who are being managed with:</strong><ul><li><strong>Watchful waiting </strong>— prostate-specific antigen (PSA) levels should be measured at least once a year.<ul><li>Digital rectal examination (DRE) is not recommended on a routine basis while the PSA level remains at baseline values.</li></ul></li><li><strong>Active surveillance, </strong>see Table 1 Protocol for active surveillance, in the section on active surveillance. </li><li><strong>Radical treatment </strong>—<strong> </strong>PSA levels should be measured no earlier than 6 weeks after treatment, then at least every 6 months for 2 years, and once a year thereafter.<ul><li>After at least two years, follow-up can be carried out by telephone or secure electronic communications to men with a stable PSA level who have had no significant treatment complications.</li></ul></li></ul></li><li>If biochemical relapse (rising PSA level) occurs, an estimate of PSA doubling time should be calculated based on a minimum of 3 measurements over at least 6 months.</li><li>Refer men with evidence of significant disease progression (rapidly rising PSA level or bone pain) to a urological cancer specialist.</li></ul><!-- end field 397a8ddc-42da-487e-a9dd-a75400fc378b --><!-- end item 73b7f09c-7e8c-4616-b0b0-a75400fc36de -->","subChapters":[{"id":"1c46338e-7de6-5df2-9fe9-f2e34fa832b0","slug":"basis-for-recommendation-844","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 65031a14-cb78-498b-8c8b-a75400fc3790 --><h4>Basis for recommendation</h4><!-- end field 65031a14-cb78-498b-8c8b-a75400fc3790 -->","summary":null,"htmlStringContent":"<!-- begin item 84403056-c234-40e2-830c-a75400fc3790 --><!-- begin field 61f54daf-d82a-4316-bcac-a75400fc3790 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><!-- end field 61f54daf-d82a-4316-bcac-a75400fc3790 --><!-- end item 84403056-c234-40e2-830c-a75400fc3790 -->","subChapters":[]}]},{"id":"26cbc36f-16d4-5602-90bb-7b1f9d0b27dc","slug":"adverse-effects-of-hormonal-therapies-including-orchidectomy","fullItemName":"Adverse effects of hormonal therapies including orchidectomy","depth":3,"htmlHeader":"<!-- begin field 70dba48d-2e6f-419c-bb60-669a6b111e1f --><h3>How should I manage adverse effects of hormonal therapies, including orchidectomy, in men with prostate cancer?</h3><!-- end field 70dba48d-2e6f-419c-bb60-669a6b111e1f -->","summary":null,"htmlStringContent":"<!-- begin item 42ce1d68-2e8d-49a5-b2ea-e50dd5187485 --><!-- begin field a99cc8b8-f785-4bcb-8b5d-8db56d6eaf03 --><ul><li><strong>Hot flushes</strong><ul><li>Offer medroxyprogesterone acetate 20 mg per day, initially for a period of 10 weeks. <ul><li>Evaluate the effect at the end of this treatment period.</li></ul></li><li>Consider cyproterone acetate 50 mg twice a day for 4 weeks if medroxyprogesterone is not effective, or not tolerated.</li><li>Explain that there is no strong evidence to support the use of complementary therapies to treat hot flushes.</li></ul></li><li><strong>Fatigue</strong><ul><li>Offer men who are starting or taking androgen deprivation therapy supervised resistance and aerobic exercise at least twice a week for 12 weeks to reduce fatigue and improve quality of life.</li></ul></li><li><strong>Osteoporosis</strong><ul><li>Do not routinely offer bisphosphonates to prevent osteoporosis in men taking androgen deprivation therapy.</li><li>Consider assessing the fracture risk in men taking androgen deprivation therapy. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/management/assessment/#how-to-assess\">assessing a person for fragility fracture risk</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.<ul><li>Offer bisphosphonates to men who have osteoporosis.</li><li>Consider denosumab for men in whom bisphosphonates are contraindicated, or not tolerated. </li></ul></li></ul></li><li><strong>Gynaecomastia</strong><ul><li>For men starting long-term bicalutamide monotherapy (longer than 6 months), offer referral to a specialist for prophylactic radiotherapy to both breast buds within the first month of treatment. </li><li>If radiotherapy is unsuccessful, consider tamoxifen weekly. </li></ul></li></ul><!-- end field a99cc8b8-f785-4bcb-8b5d-8db56d6eaf03 --><!-- end item 42ce1d68-2e8d-49a5-b2ea-e50dd5187485 -->","subChapters":[{"id":"a28ceb0f-cf34-5191-9ff7-81859a7ffb16","slug":"basis-for-recommendation-531","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5b0378d7-9171-4f56-9d52-d4b13003c42f --><h4>Basis for recommendation</h4><!-- end field 5b0378d7-9171-4f56-9d52-d4b13003c42f -->","summary":null,"htmlStringContent":"<!-- begin item 531aca26-bc8a-4ef6-bde4-4124ef854aa6 --><!-- begin field f0c9c691-ac67-4b08-9d34-f9578125b9a7 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and managemen</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><!-- end field f0c9c691-ac67-4b08-9d34-f9578125b9a7 --><!-- end item 531aca26-bc8a-4ef6-bde4-4124ef854aa6 -->","subChapters":[]}]},{"id":"cc27c9a6-85c2-5f5c-9d7a-d0d48253608a","slug":"palliative-care-pain","fullItemName":"Palliative care and pain","depth":3,"htmlHeader":"<!-- begin field 688e59f2-f1dd-4f6b-9b23-d4bf96c1e3f4 --><h3>How should I manage palliative care and pain in a man with prostate cancer?</h3><!-- end field 688e59f2-f1dd-4f6b-9b23-d4bf96c1e3f4 -->","summary":null,"htmlStringContent":"<!-- begin item 3ecd7501-8ac9-4894-82ad-f411f23654da --><!-- begin field b61804f1-500d-40a5-a3e5-d81e08275dac --><ul><li>For information on palliative care, and the management of cancer pain, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/palliative-cancer-care-pain/\">Palliative cancer care - pain</a>. </li></ul><!-- end field b61804f1-500d-40a5-a3e5-d81e08275dac --><!-- end item 3ecd7501-8ac9-4894-82ad-f411f23654da -->","subChapters":[]},{"id":"cee47bdf-a2f4-577c-9b33-32e4c48e1e23","slug":"radiation-induced-enteropathy","fullItemName":"Radiation-induced enteropathy","depth":3,"htmlHeader":"<!-- begin field 87e51a21-5750-4213-84d1-94da60f68cad --><h3>How should I manage radiation-induced enteropathy in men with prostate cancer?</h3><!-- end field 87e51a21-5750-4213-84d1-94da60f68cad -->","summary":null,"htmlStringContent":"<!-- begin item 622deb91-84c3-4edd-a95e-c7495bdd77a8 --><!-- begin field e68ed8c7-9b0b-487d-bb3e-c4f7cf9574ce --><ul><li>Ensure that men with signs or symptoms of radiation-induced enteropathy are offered care from a healthcare team with expertise in radiation-induced enteropathy.<ul><li>Symptoms may include diarrhoea, faecal urgency, steatorrhoea or rectal pain.</li></ul></li><li>Specialist assessment is likely to involve sigmoidoscopy to ascertain the nature of the radiation injury and exclude such conditions as inflammatory bowel disease and cancer of the large bowel.</li></ul><!-- end field e68ed8c7-9b0b-487d-bb3e-c4f7cf9574ce --><!-- end item 622deb91-84c3-4edd-a95e-c7495bdd77a8 -->","subChapters":[{"id":"68160277-ef72-5def-bdd1-a687e10dfa32","slug":"basis-for-recommendation-50c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d6ab62c5-2464-4e85-ab9b-fe60d3a72b1e --><h4>Basis for recommendation</h4><!-- end field d6ab62c5-2464-4e85-ab9b-fe60d3a72b1e -->","summary":null,"htmlStringContent":"<!-- begin item 50c0b2b9-4d8b-4e90-8808-8ac13505e659 --><!-- begin field d1d6da0b-e886-49de-9b97-e03080074298 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and managemen</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>] and expert opinion in a narrative review <em>Radiation-induced small bowel disease: latest developments and clinical guidance</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">Stacey, 2014</a>].</p><!-- end field d1d6da0b-e886-49de-9b97-e03080074298 --><!-- end item 50c0b2b9-4d8b-4e90-8808-8ac13505e659 -->","subChapters":[]}]},{"id":"60db5636-1d27-598a-84cd-4de78fe199c4","slug":"sexual-dysfunction","fullItemName":"Sexual dysfunction","depth":3,"htmlHeader":"<!-- begin field 24ad5dc3-e72b-4e71-90d0-014ce1acbf8a --><h3>How should I manage sexual dysfunction in men with prostate cancer?</h3><!-- end field 24ad5dc3-e72b-4e71-90d0-014ce1acbf8a -->","summary":null,"htmlStringContent":"<!-- begin item 821b3ef3-e549-4fe1-a868-7ec712a3c66b --><!-- begin field e84e2e2c-12fd-4d30-8c06-aa1dd49e14e9 --><ul><li>Tell men (and, if they wish, their partner), before starting androgen deprivation therapy that it may cause a loss of libido and possible sexual function.<ul><li>Advise men about the possible loss of ejaculation and fertility associated with therapy, and offer sperm storage.</li></ul></li><li>Ensure men have access to a sexual health specialist. <ul><li>Consider referring men (and their partner) for psychosexual counselling.</li></ul></li><li>Offer a phosphodiesterase-5 (PDE-5) inhibitor, such as sildenafil, tadalafil, or vardenafil, to men who experience loss of erectile function. <ul><li>If PDE-5 inhibitors are ineffective or contraindicated, offer a choice of:<ul><li>Intraurethral inserts.</li><li>Penile injections.</li><li>Penile prostheses.</li><li>Vacuum devices.</li></ul></li></ul></li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a>.</li></ul><!-- end field e84e2e2c-12fd-4d30-8c06-aa1dd49e14e9 --><!-- end item 821b3ef3-e549-4fe1-a868-7ec712a3c66b -->","subChapters":[{"id":"61837859-14f3-5c7c-84d2-07f77c5fa3ce","slug":"basis-for-recommendation-234","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d53989cd-ca87-4c4e-918a-455773438de3 --><h4>Basis for recommendation</h4><!-- end field d53989cd-ca87-4c4e-918a-455773438de3 -->","summary":null,"htmlStringContent":"<!-- begin item 234f2793-cb3d-4323-97f1-05c2efc66325 --><!-- begin field 5e83c9c1-804f-4c76-91bd-60b708725bd9 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><!-- end field 5e83c9c1-804f-4c76-91bd-60b708725bd9 --><!-- end item 234f2793-cb3d-4323-97f1-05c2efc66325 -->","subChapters":[]}]},{"id":"95e57896-75b9-542e-b1d2-5dc7bf97be12","slug":"suspected-spinal-cord-compression","fullItemName":"Suspected spinal cord compression","depth":3,"htmlHeader":"<!-- begin field bda4d81f-4950-4593-a83c-10a41b50e5ef --><h3>How should I manage suspected spinal cord compression in men with prostate cancer?</h3><!-- end field bda4d81f-4950-4593-a83c-10a41b50e5ef -->","summary":null,"htmlStringContent":"<!-- begin item 7a3b89ff-6ca6-49d8-b758-237e33c5d8d0 --><!-- begin field c180f330-0ed2-4ec0-b221-75b7f681ee0b --><ul><li>Suspected spinal cord compression is a medical emergency. It must be diagnosed and treated before there is significant neurological compromise.</li><li>For more information, see the <a class=\"topic-reference external-reference\" href=\"/topics/palliative-cancer-care-pain/management/spinal-cord-compression/\">Scenario: Spinal cord compression</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-cancer-care-pain/\">Palliative cancer care - pain</a>.</li></ul><!-- end field c180f330-0ed2-4ec0-b221-75b7f681ee0b --><!-- end item 7a3b89ff-6ca6-49d8-b758-237e33c5d8d0 -->","subChapters":[{"id":"9ac8ce51-6686-5e9e-9d4d-ccb405ec4874","slug":"basis-for-recommendation-6b8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b9c9f2a7-79c5-494a-a2a4-ce2f8d9313e4 --><h4>Basis for recommendation</h4><!-- end field b9c9f2a7-79c5-494a-a2a4-ce2f8d9313e4 -->","summary":null,"htmlStringContent":"<!-- begin item 6b8431a5-38c6-40bc-8976-7afec02e2e36 --><!-- begin field 89482461-dfd4-4da0-9c1d-b2a5af34a18c --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline<em> </em><em>Metastatic spinal cord compression in adults: risk assessment, diagnosis and management</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2008</a>]<em>.</em></p><!-- end field 89482461-dfd4-4da0-9c1d-b2a5af34a18c --><!-- end item 6b8431a5-38c6-40bc-8976-7afec02e2e36 -->","subChapters":[]}]},{"id":"73cb2380-e62e-5726-8da6-c3e375703024","slug":"urinary-symptoms","fullItemName":"Urinary symptoms","depth":3,"htmlHeader":"<!-- begin field ee6e96fb-ebe8-47b2-95f4-77bc0a2e3ad9 --><h3>How should I manage urinary incontinence or retention in men with prostate cancer?</h3><!-- end field ee6e96fb-ebe8-47b2-95f4-77bc0a2e3ad9 -->","summary":null,"htmlStringContent":"<!-- begin item aab42a21-8667-4f7b-a55c-e566ff9d08e0 --><!-- begin field 52f9a049-0ef3-41ad-a3db-9e19e6faad47 --><ul><li>Warn men undergoing radical treatment for prostate cancer of the likely effects of the treatment on their urinary function.<ul><li>Offer men experiencing urinary symptoms before treatment a urological assessment. </li></ul></li><li>Ensure men with troublesome urinary symptoms after treatment have access to specialist continence services for assessment, diagnosis and conservative treatment. <ul><li>Management options coping strategies, pelvic floor muscle re-education, bladder retraining or medicines. </li></ul></li><li>Refer men with intractable urinary incontinence to a specialist surgeon for consideration of an artificial urinary sphincter.</li></ul><!-- end field 52f9a049-0ef3-41ad-a3db-9e19e6faad47 --><!-- end item aab42a21-8667-4f7b-a55c-e566ff9d08e0 -->","subChapters":[{"id":"ebb20a40-5d9a-5eac-a81e-54b8625fc002","slug":"basis-for-recommendation-5e2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4ae4512b-5a5b-4b5f-944c-2b7c5b12d4f6 --><h4>Basis for recommendation</h4><!-- end field 4ae4512b-5a5b-4b5f-944c-2b7c5b12d4f6 -->","summary":null,"htmlStringContent":"<!-- begin item 5e2d09ca-c4cb-47e4-95d8-fa89e64815ec --><!-- begin field 0ec83677-5a3f-431c-ae7a-aca48a5250bb --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><!-- end field 0ec83677-5a3f-431c-ae7a-aca48a5250bb --><!-- end item 5e2d09ca-c4cb-47e4-95d8-fa89e64815ec -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}